Where does Dyne Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$120.85M-4.8%	-$111.96M-25.0%	-$108.04M-11.2%	-$110.86M-70.3%	-$115.36M-75.7%
Depreciation and amortization	$550K+9.6%	$521K+15.8%	$500K+25.0%	$500K+25.0%	$502K+30.1%
Stock-based compensation	$13.08M+0.5%	$11.23M+7.1%	$11.08M+26.7%	$10.52M+56.2%	$13.02M-34.6%
Gain (loss) on sale of assets	-$30K+68.4%	——	——	——	-$95K-4,850%
Change in accounts payable	-$4.8M+44.1%	——	$18.47M—	——	-$8.6M+70.1%
Change in other assets	-$28K—	$0—	$15.79M+319%	-$2.8M-189%	$0-100%
Net cash from operating activities	-$144.92M-36.9%	-$111.83M-32.6%	-$90.78M-21.6%	-$94.7M-72.6%	-$105.89M-34.8%
Capital expenditures	$221K-77.5%	$484K-55.0%	$395K+56.1%	$60K-93.0%	$981K+414%
Net cash from investing activities	-$2.39M-264%	$0+100%	-$37.97M-95.7%	$6.77M—	$1.46M+101%
Proceeds from issuance of debt	——	$49.45M—	——	——	——
Proceeds from issuance of common stock	$0-100%	$377.7M—	$215.8M—	——	$140.65M+91.1%
Payment of debt issuance costs	$30K—	$9K—	——	——	$0—
Net cash from financing activities	$7.06M-95.0%	$430.97M+11,753%	$217.33M+1,107%	$100.77M-73.5%	$141.24M-65.4%
Net increase (decrease) in cash	-$140.25M-481%	$320.12M—	$88.58M—	$12.85M-96.2%	$36.81M-75.5%
Interest paid	$3.63M—	$2.52M—	——	——	$0—
Gain (Loss) on Disposition of Assets	-$30K+68.4%	——	——	——	-$95K-4,850%
Increase (Decrease) in Accounts Payable and Other Operating Liabilities	-$4.8M+44.1%	——	$18.47M—	——	-$8.6M+70.1%
Increase (Decrease) in Prepaid Expense and Other Assets	$32.85M+757%	——	-$389K—	——	-$5M-223%
Non Cash Lease Expense	$116K+54.7%	$35K-74.3%	$96K-29.4%	——	$75K-56.6%
Payments To Acquire Other Productive Assets	——	$4.7M—	$4.7M—	$4.7M—	$4.7M—
Payment Of Issuance Costs From Public Offering Of Common Stock	$424K—	——	——	——	$0—
Payments Of Debt Issuance Costs	$30K—	$9K—	——	——	$0—
Proceeds From Vendor Financing Arrangement	$6.79M—	——	——	——	$0—
Repayments Under Vendor Financing Arrangement	$579K—	——	——	——	$0—
Accrued payables for capital expenditures	$77K+166%	$65K+235%	-$364K-858%	$335K+1,341%	$29K+7.4%
Offering Costs Included In Accounts Payable Or Accrued Expenses	——	$106K—	$106K—	$106K—	$106K—
Free cash flow	-$145.14M-35.8%	-$112.32M-31.5%	-$91.17M-21.8%	-$94.76M-70.1%	-$106.87M-35.8%
Free cash flow	-$145.14M-35.8%	-$112.32M-31.5%	-$91.17M-21.8%	-$94.76M-70.1%	-$106.87M-35.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dyne Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.